| Autor: |
Panagiotis Ntziachristos, Giuseppe Basso, Benedetta Accordi, Francoise Pflumio, Rama K. Mishra, Keng Boon Wee, Aristotelis Tsirigos, Adriana Heguy, Ernesto Guccione, Young Ah Goo, Iannis Aifantis, Tom Taghon, Pieter Van Vlierberghe, Bruno Palhais, Ping Zhu, Marc L. Mendillo, Hiam Abdala-Valencia, Yuliya Politanska, Irawati Kandela, Hu Li, Cheng Zhang, Maddalena Paganin, Silvia Bresolin, Radhika Rawat, Emily J. Rendleman, David R. Amici, Yoh-Hei Takahashi, Qi Jin, Szymon K. Filip, George Yacu, Limin Sun, Anna Kuchmiy, Christian Marier, Tommaso Tabaglio, Alireza Khodadadi-Jamayran, Celestia Fang, Julien Calvo, Blanca T. Gutierrez Diaz, Byoung-Kyu Cho, Valentina Serafin, Adam H. Lorch, Eric Wang, Cuijuan Han, Yalu Zhou |
| Rok vydání: |
2023 |
| Popis: |
Splicing alterations are common in diseases such as cancer, where mutations in splicing factor genes are frequently responsible for aberrant splicing. Here we present an alternative mechanism for splicing regulation in T-cell acute lymphoblastic leukemia (T-ALL) that involves posttranslational stabilization of the splicing machinery via deubiquitination. We demonstrate there are extensive exon skipping changes in disease, affecting proteasomal subunits, cell-cycle regulators, and the RNA machinery. We present that the serine/arginine-rich splicing factors (SRSF), controlling exon skipping, are critical for leukemia cell survival. The ubiquitin-specific peptidase 7 (USP7) regulates SRSF6 protein levels via active deubiquitination, and USP7 inhibition alters the exon skipping pattern and blocks T-ALL growth. The splicing inhibitor H3B-8800 affects splicing of proteasomal transcripts and proteasome activity and acts synergistically with proteasome inhibitors in inhibiting T-ALL growth. Our study provides the proof-of-principle for regulation of splicing factors via deubiquitination and suggests new therapeutic modalities in T-ALL.Significance:Our study provides a new proof-of-principle for posttranslational regulation of splicing factors independently of mutations in aggressive T-cell leukemia. It further suggests a new drug combination of splicing and proteasomal inhibitors, a concept that might apply to other diseases with or without mutations affecting the splicing machinery.This article is highlighted in the In This Issue feature, p. 1241 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
